Clinical trial
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
NCT00060515 · Repligen Corporation, Industry · Terminated
Key facts
| NCT number | NCT00060515 |
|---|---|
| Title | RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease |
| Official title | An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases |
| Lead sponsor | Repligen Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Mitochondrial Diseases |
| Intervention type | Drug |
| Interventions | RG2133 (2', 3', 5'-tri-O-acetyluridine) |
| Enrollment | 12 |
| First posted | May 8, 2003 |
| Last update posted | Aug 5, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: